From the Department of Cancer Imaging (A.L.)
Sir Peter MacCallum Department of Oncology (A.L.).
AJNR Am J Neuroradiol. 2020 Nov;41(11):1982-1988. doi: 10.3174/ajnr.A6769. Epub 2020 Sep 10.
Radiogenomics aims to predict genetic markers based on imaging features. The critical importance of molecular markers in the diagnosis and management of intracranial gliomas has led to a rapid growth in radiogenomics research, with progressively increasing complexity. Despite the advances in the techniques being examined, there has been little translation into the clinical domain. This has resulted in a growing disconnect between cutting-edge research and assimilation into clinical practice, though the fundamental goal is for these techniques to improve patient care. The goal of this review, therefore, is to discuss possible clinical scenarios in which the addition of radiogenomics may aid patient management. This includes facilitating patient counseling, determining optimal patient management when complete molecular characterization is not possible, reclassifying tumors, and overcoming some of the limitations of histologic assessment. The review also discusses considerations for selecting relevant radiogenomic features based on the clinical setting.
放射组学旨在基于影像学特征预测遗传标志物。分子标志物在颅内神经胶质瘤的诊断和治疗中的关键重要性促使放射组学研究迅速发展,其复杂性也逐渐增加。尽管所检查的技术取得了进展,但很少有转化为临床领域。这导致了前沿研究与临床实践之间的脱节日益严重,尽管其根本目标是这些技术能够改善患者的护理。因此,本综述的目的是讨论放射组学可能有助于患者管理的可能临床情况。这包括为患者咨询提供便利、在无法进行完整分子特征分析时确定最佳患者管理、对肿瘤进行重新分类以及克服组织学评估的一些局限性。该综述还讨论了根据临床情况选择相关放射组学特征的注意事项。